The next steps will be to evaluate the effects of pretreatment with an immune checkpoint inhibitor (e.g., anti-PD-1 antibody) or an anti-stemness drug (e.g., small molecule inhibitor of Bmi-1) based on recent evidence from the Wang group in HNSCC [114]. This evidence concerns the gene BMI1 and head and neck squamous cell carcinoma.